Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway.

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

Cases in Texas and other states are on the rise, but most of the infected were not vaccinated. Here’s what to know about the ...

Fox News contributor Dr. Marty Makary was officially confirmed to lead the FDA in Trump's second administration after a vote ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A woman receives a booster dose of Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) at the Police hospital in Bangkok ...

The San Carlos, Calif.-based firm will offer top-line safety, tolerability, and immunogenicity data, to be followed by top-line data with the booster dose by the end of this year.

Pfizer is trading at a ridiculously cheap valuation ... In a 48-week phase 2 trial, participants on the highest dose (2.4 mg) of pemvidutide lost an average of 15.6% of their body weight.

In response, Israel is the first country in the world to approve a third dose of the vaccine as a booster shot, according to The Times of Israel. Last week, Pfizer asked countries to approve a ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...